The global high throughput screening market size was estimated to be USD 23.38 billion in 2023 and is expected to reach USD 71.10 billion by 2034 with a CAGR of 10.64% during the forecast period 2024-2034. The market will grow as a result of factors such as expanding biotech and pharmaceutical R&D, expanding personalized medicine focus, technological advancements in HTS platforms, growing use of HTS in academic and research institutions, and government support and funding.
Innovations in high-throughput screening (HTS) technologies, including automation, miniaturization, and the integration of artificial intelligence (AI), have markedly improved the efficiency, accuracy, and throughput of screening processes. These advancements are making HTS more accessible and cost-effective, thereby accelerating its adoption among research laboratories and pharmaceutical companies. For instance, in January 2023, Charles River Laboratories International, Inc. purchased SAMDI Tech, Inc., a prominent provider of HTS solutions, to broaden its HTS portfolio.
By product and services, the consumables products segment accounted for the highest revenue-grossing segment in the global high throughput screening market in 2023 owing to the increased demand for reagents, assay kits, and other essential materials used in screening processes. For instance, PerkinElmer advanced research and development efforts with the introduction of the EnVison Nexus Multimode plate reader in February 2023. Additionally, the services segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising outsourcing of HTS services to contract research organizations (CROs) and the growing need for specialized screening services.
By technology, the cell-based assay technology segment accounted for the highest revenue-grossing segment in the global high throughput screening market in 2023 owing to the growing adoption of cell-based assays for drug discovery and the ability to provide more physiologically relevant data compared to traditional biochemical assays. For instance, Bio-Rad Laboratones, Inc. (US) introduced three new StartBright Red Dyes in May: StarBright Red 715, 775, and 815. These dyes offer improved flexibility and choice for traditional and full-spectrum multicolor flow cytometry panels. Additionally, the lab-on-a-chip (LOC) technology segment is predicted to grow at the fastest CAGR during the forecast period due to the miniaturization of assays, cost-effectiveness, and ability to integrate multiple laboratory functions into a single chip, increasing screening efficiency.
By application, the drug discovery programs segment accounted for the highest revenue-grossing segment in the global high throughput screening market in 2023 owing to the increasing investment in R&D by pharmaceutical companies and the need to rapidly screen vast compound libraries to identify potential drug candidates. For instance, in April 2024, Metrion Biosciences Limited and Enamine Ltd announced that they will be combining Enamine's compound libraries into Metrion's HTS services. This partnership will help Metrion become more proficient in drug discovery and development. Additionally, the biochemical screening segment is predicted to grow at the fastest CAGR during the forecast period due to the increased focus on identifying biological markers and enzymes in the early stages of drug discovery.
By end-user, the pharmaceutical & biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global high throughput screening market in 2023 due to the high adoption of HTS technologies in drug discovery and the expansion of pharmaceutical pipelines. For instance, in February 2023, Beckman Coulter Life Sciences established a partnership with Sciex, a provider of analytical technology, to obtain procedures for high-throughput screening and synthetic biology studies. The corporation will benefit from this calculated action by having more operating capacity and higher income. Additionally, the academic & research institutes segment is predicted to grow at the fastest CAGR during the forecast period due to the increased academic research collaborations and the adoption of HTS for basic research and early-stage drug discovery.
North American region is anticipated for the highest revenue share during the forecast period owing to the well-established pharmaceutical and biotechnology industries, significant investments in drug discovery research, and the presence of key market players, as well as supportive government funding for research and development activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding pharmaceutical sector, increasing investments in R&D, rising healthcare infrastructure, and the growing adoption of high throughput screening technologies in countries like China, India, and Japan. For instance, in October 2023, mass spectrometry solutions for newborn screening were developed by Revvity Inc. (US) in partnership with SCIEX, a division of Danaher Corporation (US).
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Innovations in high-throughput screening (HTS) technologies, including automation, miniaturization, and the integration of artificial intelligence (AI), have markedly improved the efficiency, accuracy, and throughput of screening processes. These advancements are making HTS more accessible and cost-effective, thereby accelerating its adoption among research laboratories and pharmaceutical companies. For instance, in January 2023, Charles River Laboratories International, Inc. purchased SAMDI Tech, Inc., a prominent provider of HTS solutions, to broaden its HTS portfolio.
By product and services, the consumables products segment accounted for the highest revenue-grossing segment in the global high throughput screening market in 2023 owing to the increased demand for reagents, assay kits, and other essential materials used in screening processes. For instance, PerkinElmer advanced research and development efforts with the introduction of the EnVison Nexus Multimode plate reader in February 2023. Additionally, the services segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising outsourcing of HTS services to contract research organizations (CROs) and the growing need for specialized screening services.
By technology, the cell-based assay technology segment accounted for the highest revenue-grossing segment in the global high throughput screening market in 2023 owing to the growing adoption of cell-based assays for drug discovery and the ability to provide more physiologically relevant data compared to traditional biochemical assays. For instance, Bio-Rad Laboratones, Inc. (US) introduced three new StartBright Red Dyes in May: StarBright Red 715, 775, and 815. These dyes offer improved flexibility and choice for traditional and full-spectrum multicolor flow cytometry panels. Additionally, the lab-on-a-chip (LOC) technology segment is predicted to grow at the fastest CAGR during the forecast period due to the miniaturization of assays, cost-effectiveness, and ability to integrate multiple laboratory functions into a single chip, increasing screening efficiency.
By application, the drug discovery programs segment accounted for the highest revenue-grossing segment in the global high throughput screening market in 2023 owing to the increasing investment in R&D by pharmaceutical companies and the need to rapidly screen vast compound libraries to identify potential drug candidates. For instance, in April 2024, Metrion Biosciences Limited and Enamine Ltd announced that they will be combining Enamine's compound libraries into Metrion's HTS services. This partnership will help Metrion become more proficient in drug discovery and development. Additionally, the biochemical screening segment is predicted to grow at the fastest CAGR during the forecast period due to the increased focus on identifying biological markers and enzymes in the early stages of drug discovery.
By end-user, the pharmaceutical & biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global high throughput screening market in 2023 due to the high adoption of HTS technologies in drug discovery and the expansion of pharmaceutical pipelines. For instance, in February 2023, Beckman Coulter Life Sciences established a partnership with Sciex, a provider of analytical technology, to obtain procedures for high-throughput screening and synthetic biology studies. The corporation will benefit from this calculated action by having more operating capacity and higher income. Additionally, the academic & research institutes segment is predicted to grow at the fastest CAGR during the forecast period due to the increased academic research collaborations and the adoption of HTS for basic research and early-stage drug discovery.
North American region is anticipated for the highest revenue share during the forecast period owing to the well-established pharmaceutical and biotechnology industries, significant investments in drug discovery research, and the presence of key market players, as well as supportive government funding for research and development activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding pharmaceutical sector, increasing investments in R&D, rising healthcare infrastructure, and the growing adoption of high throughput screening technologies in countries like China, India, and Japan. For instance, in October 2023, mass spectrometry solutions for newborn screening were developed by Revvity Inc. (US) in partnership with SCIEX, a division of Danaher Corporation (US).
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product and Services, Technology, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: High Throughput Screening Market Report 2023 - 2034
High Throughput Screening Market Analysis & Forecast by Product and Services 2023 - 2034 (Revenue USD Bn)
- Consumables
- Reagents & Assay Kits
- Laboratory Equipment
- Instruments
- Liquid Handling Systems
- Detection Systems
- Other Instruments
- Instruments
- Services
- Software
High Throughput Screening Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Cell-based Assays
- Fluorometric Imaging Plate Reader Assays
- Reporter based Assays
- 3D - Cell Cultures
- 2D - Cell Cultures
- Reporter-based Assays
- Perfusion Cell Culture
- Lab-on-a-chip Technology (LOC)
- Label-free Technology
- Ultra-High Throughput Screening
High Throughput Screening Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Drug Discovery Programs
- Chemical Biology Programs
- Biochemical Screening
- Cell & Organ-based Screening
High Throughput Screening Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical & Biopharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Others
High Throughput Screening Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. High Throughput Screening Market: Product and Services Estimates & Trend Analysis
8. High Throughput Screening Market: Technology Estimates & Trend Analysis
9. High Throughput Screening Market: Application Estimates & Trend Analysis
10. High Throughput Screening Market: End-User Estimates & Trend Analysis
11. Regional Market Analysis
12. North America High Throughput Screening Market
13. Europe Global High Throughput Screening Market
14. Asia Pacific Global High Throughput Screening Market
15. Latin America Global High Throughput Screening Market
16. MEA Global High Throughput Screening Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- PerkinElmer Inc.
- Agilent Technologies Inc.
- Eppendorf AG
- Corning Incorporated
- Bio-Rad Laboratories Inc.
- Roche Holding AG
- Sierra Instruments Inc.
- Tecan Group Ltd.
- Hamilton Company
- BMG LABTECH GmbH
- Danaher Corporation
- Sartorius AG
- MilliporeSigma (Merck KGaA)
- Promega Corporation.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 23.38 Billion |
| Forecasted Market Value ( USD | $ 71.1 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
